Capitalizing on CRISPR

With broad basic science and translational applications, CRISPR is driving innovative life science and medical research. Learn more in this poster from Horizon Discovery.

Horizon Discovery
Nov 30, 2015

Genetic engineering has been boosted by the discovery and characterization of CRISPR-associated Cas9 RNA-guided endonuclease. This technology enables rapid genetic perturbation and manipulation, as well as genome-wide functional screening. With broad basic science and translational applications, this technology is driving innovative life science and medical research. 

Horizon Discovery is a life science company that supplies research tools and services to organizations engaged in translational genomics research and the development of personalized medicines. Horizon’s core capabilities are built around our proprietary translational genomics platform, a high-precision and flexible suite of gene editing tools that include CRISPR, rAAV and ZFNs, enabling us to alter almost any endogenous gene sequence of human or mammalian cell-lines. 

 We offer over 20,000 catalogue cell line and in vivo products, models that accurately recapitulate the disease-causing mutations found in genetically based diseases. These ‘patients-in-a-test-tube’ are being used by customers to identify the effect of individual or compound...

 Finally, we also provide custom cell line and in vivo model generation services for research and bioproduction applications, and a wide selection of specialist contract research and custom screening services (including drug combination and CRISPR-based screening).

 Our diverse and international customer base comprises over 1,200 organizations across more than 50 countries, including major pharmaceutical, biotechnology and diagnostic companies, as well as leading academic research centers and clinical labs.

 Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD.”

Download this poster from Horizon Discovery to learn more!

Interested in reading more?

Capitalizing on CRISPR

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?